Vor Biopharma (NASDAQ: VOR) updates and wins approval for 2021 equity plan
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Vor Biopharma Inc. reported results from its 2026 annual stockholder meeting and changes to its equity incentive plan. Stockholders approved an amended and restated 2021 Equity Incentive Plan that keeps the automatic annual share increase but now bases it on both issued and outstanding common shares and shares issuable from pre-funded warrants. The amended plan also provides that, unless an award agreement states otherwise, unvested time-based awards held by an employee will fully vest if the employee’s service ends due to death. Two Class II directors, Andrew Levin and Fouad Namouni, were re-elected, the equity plan amendment was approved, and Ernst & Young LLP was ratified as independent auditor for the year ending December 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.07, 9.01
2 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Evergreen rate: 4% annual increase
Shares represented: 34,012,004 shares
Equity plan approval votes: 20,146,430 for / 6,767,428 against
+4 more
7 metrics
Evergreen rate
4% annual increase
Automatic yearly share reserve increase through calendar year 2035
Shares represented
34,012,004 shares
Common stock present or by proxy at 2026 annual meeting, 62.77% of eligible
Equity plan approval votes
20,146,430 for / 6,767,428 against
Stockholder vote on Amended 2021 Equity Incentive Plan
Auditor ratification
33,877,004 for
Votes to ratify Ernst & Young LLP for year ending December 31, 2026
Director Levin votes
25,797,081 for / 120,813 withheld
Election of Andrew Levin, M.D., Ph.D., as Class II director
Director Namouni votes
22,825,938 for / 4,091,956 withheld
Election of Fouad Namouni, M.D., as Class II director
Evergreen end year
2035
Evergreen provision applies through calendar year 2035
Key Terms
Evergreen Provision, pre-funded warrants, time-based awards, broker non-votes, +1 more
5 terms
Evergreen Provision financial
"The 2021 Plan provides that the number of shares reserved for issuance thereunder automatically increases on each January 1 by 4%... (the “Evergreen Provision”)."
An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.
pre-funded warrants financial
"based on the sum... of both issued and outstanding shares of Common Stock and shares of Common Stock issuable upon the exercise of any pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
time-based awards financial
"outstanding and unvested time-based awards under the Amended 2021 Plan will become fully vested if the continuous service of a participant..."
broker non-votes financial
"Andrew Levin, M.D., Ph.D. | 25,797,081 | 120,813 | 7,094,110 broker non-votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm regulatory
"the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
FAQ
What did Vor Biopharma (VOR) change in its 2021 Equity Incentive Plan?
Vor Biopharma updated its 2021 Equity Incentive Plan so the annual share increase now reflects both issued and outstanding common shares and shares from pre-funded warrants. It also adds full vesting of time-based awards if an employee’s service ends because of death, unless an award agreement states otherwise.
Did Vor Biopharma (VOR) stockholders approve the amended 2021 equity plan?
Yes. Stockholders approved the Amended 2021 Plan with 20,146,430 votes for, 6,767,428 against, 4,036 abstentions, and 7,094,110 broker non-votes. This approval allows the company to apply the revised evergreen calculation and the updated vesting treatment on qualifying employee awards.
Who was elected to Vor Biopharma’s (VOR) Board at the 2026 annual meeting?
Andrew Levin, M.D., Ph.D., and Fouad Namouni, M.D., were re-elected as Class II directors. Levin received 25,797,081 votes for and 120,813 withheld, while Namouni received 22,825,938 votes for and 4,091,956 withheld, along with 7,094,110 broker non-votes for each nominee.
Which audit firm will review Vor Biopharma’s (VOR) 2026 financials?
Stockholders ratified Ernst & Young LLP as Vor Biopharma’s independent registered public accounting firm for the year ending December 31, 2026. The ratification vote was 33,877,004 shares for, 133,499 against, and 1,501 abstentions, confirming continued engagement of the same audit firm.
How does the evergreen provision work in Vor Biopharma’s Amended 2021 Plan?
The evergreen provision increases the share reserve each January 1 through 2035. Under the amended plan, the added shares are based on the prior December 31 total of issued and outstanding common shares plus shares issuable upon exercise of pre-funded warrants, aligning the pool with potential equity over time.